Lv5
1150 积分 2022-10-26 加入
PARP inhibition enhances the antitumor activity of HER3-DXd in non-small cell lung cancer
3天前
已完结
The next generation of antibody–drug conjugates
24天前
已完结
Sacituzumab tirumotecan plus pembrolizumab versus pembrolizumab in PD-L1-positive advanced non-small-cell lung cancer (OptiTROP-Lung05): interim analysis of a randomised, open-label, phase 3 trial
1个月前
已完结
Inhibition of topoisomerase I shapes antitumor immunity through the induction of monocyte-derived dendritic cells
1个月前
已完结
Mechanism of action and future perspectives of ADCs in combination with immune checkpoint inhibitors for solid tumors
1个月前
已完结
Combining antibody-drug conjugates with immunotherapy in solid tumors: current landscape and future perspectives
1个月前
已完结
Site-Selective Anti-PD-L1 Antibody–MMAE Conjugate for Enhanced NSCLC Therapy
3个月前
已完结
Nonclinical & clinical interface - extrapolation of nonclinical data to support Phase I clinical studies
3个月前
已完结
Exploring the next generation of antibody–drug conjugates
4个月前
已完结
Unlocking biological barriers: nonclinical safety considerations for RNA-based complex biologics
4个月前
已完结
皖公网安备34019202002308
